| [1] |
Behr TM, Behe M, Becker W. Diagnostic applications of radiolabeled peptides in nuclear endocrinology[J]. Q J Nucl Med, 1999, (43): 268-280.
|
| [2] |
Ronald E, Weiner and ThakurML. Radiolabeled peptides in diagnosis and therapy[J]. Semin Nuel Med, 2001, 31(4): 296-311.
|
| [3] |
Okarvi SM. Recent evelopment in 99Tcm-labelled pepide based radiopharmaceuticals: Anovervied[J]. Nucl Med Commn, 1999, 20: 1093-1113.
|
| [4] |
Taillefer R, Barnes D, Hill J, et al. 99Tcm-Apcitide and correlation with contrast enhanced venography in detection of acute deep veinthrombosis[J]. J Nucl Med, 1999, 40(12): 2029-2035.
|
| [5] |
Palestro CJ, Tomas MB, Bhargava KK, et al. 99Tcm-P483H for imaging infection: Phase 2 muhicenter trial results[J]. J Nucl Med, 1999, 40: 15P.
|
| [6] |
lles DL, Goodbody AE, Cockeram A, et al. Apilot phase Ⅱ clinical study on imaging inflammatory lesions in patients with Crohn's diseaseusing Tc-99m RP128[J]. J Nucl Med,1998, 39: 271p.
|
| [7] |
Virgolini I. New trend in peptide receptor radioligands[J]. Q J Nucl Med, 2001, 45(2): 153-159.
|
| [8] |
Otte A, Jermann E, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy[J]. Eur J Nucl Med, 1997, 24(7): 792-795.
|
| [9] |
Anderson C J, Dehdashi F, et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors[J]. J Nucl Med, 2001, 42(2): 213-221.
|
| [10] |
Reilly RM, KiarashR, Cameron RG, et al. 111In labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR[J]. J Nucl Med, 2000, 41(3): 429-438.
|